Drug Approval | November 10, 2025
Johnson & Johnson gets FDA nod for new depression treatment
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
Exemestane is a key therapeutic used in the treatment of certain types of breast cancer in postmenopausal women
Yesintek and Yesintek I.V. are approved for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients
LEQEMBI was initially approved in China in January 2024 for the treatment of Alzheimer’s disease in patients with mild cognitive impairment
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
This Product is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
The product is bioequivalent and therapeutically equivalent to the reference listed drug
The company also plans to boost its India presence by adding 1,500 beds in the next 2-3 years
The aggregate foreign investment, including investment from other foreign investors may be up to 90.1% shareholding in the company
Subscribe To Our Newsletter & Stay Updated
